Millennium and Abbott Initiate Phase I Trials of their First Genomically-Derived Drug Target for Obesity
28-Nov-2001 -
CAMBRIDGE, Mass., and ABBOTT PARK, Ill., November 27, 2001 - Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) and Abbott Laboratories, (NYSE: ABT) today announced the initiation of a Phase I clinical trial of MLN4760. This represents the first molecule directed against a genomically-derived target ...
Abbott
clinical trials
Enzyme
+5